{
    "info": {
        "nct_id": "NCT06585501",
        "official_title": "Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)",
        "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": "Inclusion criteria\n\n* Patients with pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC (limited to those diagnosed since October 1, 2017) and initiating first-line treatment between January 1, 2018, and March 31, 2023\n* Patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic GC/GEJC; HER2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard).\n\nExclusion criteria\n\n* Patients with other primary malignant tumors\n* Patients enrolled in clinical trials and receiving active anti-cancer therapy after July.1, 2017 (excluding retrospective studies).\n* Patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator"
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [
        {
            "line": "* Patients with pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC (limited to those diagnosed since October 1, 2017) and initiating first-line treatment between January 1, 2018, and March 31, 2023",
            "criterions": [
                {
                    "exact_snippets": "pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC",
                    "criterion": "GC/GEJC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "locally advanced unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosed since October 1, 2017",
                    "criterion": "diagnosis date",
                    "requirements": [
                        {
                            "requirement_type": "date",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2017.1,
                                        "unit": "year"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "initiating first-line treatment between January 1, 2018, and March 31, 2023",
                    "criterion": "treatment initiation date",
                    "requirements": [
                        {
                            "requirement_type": "date",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2018.01,
                                        "unit": "year"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2023.03,
                                        "unit": "year"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic GC/GEJC; HER2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard).",
            "criterions": [
                {
                    "exact_snippets": "Patients aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced unresectable or metastatic GC/GEJC",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-positive status",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by either tissue samples from the first biopsy or liquid biopsy samples",
                    "criterion": "biopsy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "tissue",
                                "liquid"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard",
                    "criterion": "biopsy sample preference",
                    "requirements": [
                        {
                            "requirement_type": "preference",
                            "expected_value": "tissue"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with other primary malignant tumors",
            "criterions": [
                {
                    "exact_snippets": "Patients with other primary malignant tumors",
                    "criterion": "primary malignant tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients enrolled in clinical trials and receiving active anti-cancer therapy after July.1, 2017 (excluding retrospective studies).",
            "criterions": [
                {
                    "exact_snippets": "Patients enrolled in clinical trials",
                    "criterion": "clinical trial enrollment",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "enrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving active anti-cancer therapy",
                    "criterion": "anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "receiving"
                        }
                    ]
                },
                {
                    "exact_snippets": "after July.1, 2017",
                    "criterion": "date of therapy",
                    "requirements": [
                        {
                            "requirement_type": "start date",
                            "expected_value": "> July 1, 2017"
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding retrospective studies",
                    "criterion": "study type",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "retrospective studies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator",
            "criterions": [
                {
                    "exact_snippets": "critical missing data in medical records",
                    "criterion": "medical records",
                    "requirements": [
                        {
                            "requirement_type": "data completeness",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "deemed for inclusion by the investigator",
                    "criterion": "investigator's discretion",
                    "requirements": [
                        {
                            "requirement_type": "inclusion decision",
                            "expected_value": "investigator's discretion"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": [
        {
            "line": "Inclusion criteria",
            "criterions": []
        },
        {
            "line": "Exclusion criteria",
            "criterions": []
        }
    ]
}